{
    "root": "e94a5b8c-e43f-494e-bdef-4ef365441dcf",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "RIVAROXABAN",
    "value": "20250307",
    "ingredients": [
        {
            "name": "RIVAROXABAN",
            "code": "9NDF7JZ4M3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_68579"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        }
    ],
    "indications": {
        "text": "rivaroxaban factor xa inhibitor indicated : reduce risk major cardiovascular events patients coronary artery disease ( cad ) ( 1.7 ) reduce risk major thrombotic vascular events patients peripheral artery disease ( pad ) , including patients recent lower extremity revascularization due symptomatic pad ( 1.8 )",
        "doid_entities": [
            {
                "text": "coronary artery disease (DOID:3393)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3393"
            },
            {
                "text": "artery disease (DOID:0050828)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050828"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "peripheral artery disease (DOID:0050830)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050830"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "cad pad : 2.5 mg orally twice daily without food , combination aspirin ( 75 100 mg ) daily ( 2.1 ) .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "rivaroxaban tablets usp , 2.5 mg available packages listed : 2.5 mg tablets : light yellow colored , round shaped , biconvex , film-coated tablets , debossed `` c4 `` one side `` l `` side . tablets supplied packages listed : ndc 68180-709-06 bottle containing 30 tablets ndc 68180-709-09 bottle containing 90 tablets store 25\u00b0c ( 77\u00b0f ) room temperature ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . keep reach children .",
    "adverseReactions": "rivaroxaban tablets contraindicated patients : active pathological bleeding [ ( 5.2 ) ] severe hypersensitivity reaction rivaroxaban tablets ( e.g . , anaphylactic ) [ ( 6.2 ) ]",
    "indications_original": "Rivaroxaban is a factor Xa inhibitor indicated: to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 )",
    "contraindications_original": "CAD or PAD : 2.5 mg orally twice daily with or without food, in combination with aspirin (75 to 100 mg) once daily ( 2.1 ).",
    "warningsAndPrecautions_original": "Rivaroxaban Tablets USP, 2.5 mg available in the packages listed below:\n                  \n                     \u00a0 2.5 mg tablets: Light yellow colored, round shaped, biconvex, film-coated tablets, debossed with \"C4\" on one side and \"L\" on the other side. The tablets are supplied in the packages listed:\n                  \n                  NDC 68180-709-06\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Bottle containing 30 tablets \n                  NDC 68180-709-09\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Bottle containing 90 tablets\n                  Store at 25\u00b0C (77\u00b0F) or room temperature; excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature]. \n                  Keep out of the reach of children.",
    "adverseReactions_original": "Rivaroxaban tablets are contraindicated in patients with:\n                  \n                     \u00a0 active pathological bleeding [see Warnings and Precautions (5.2)] \n                     \n                     \u00a0 severe hypersensitivity reaction to rivaroxaban tablets (e.g., anaphylactic reactions) [see Adverse Reactions (6.2)]",
    "drug": [
        {
            "name": "RIVAROXABAN",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_68579"
        }
    ]
}